Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VantagE: Rivastigmine in Vascular Dementia
NCT00099216Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2001
- Primary completion
- Nov 2005
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 10
01
Overview
A Phase 3 trial of rivastigmine in vascular dementia, sponsored by Novartis. Started Aug 2001; status: completed.
02
Drugs
rivastigmine
03
Conditions
vascular dementia
Beyond the preview
Go deeper on NCT00099216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099216.